Antioxidants Against Chemotherapy-Related Nerve Damage?
The chemotherapy drugs, Taxol (paclitaxel) and Taxotere (docetaxel) can have a beneficial impact on survival and quality of life for many people with advanced metastatic cancers. But these drugs can also incur damage to the sensory nervous system, resulting in painful tingling or numbness in the feet and hands. So uncomfortable and stressful are these symptoms that the oncologist is often forced to reduce the dosage, thus ultimately limiting the effectiveness of the treatment. One strategy that is being used with some success is the antioxidant supplement called alpha-lipoic acid, or ALA. A number of studies have found that ALA may be effective in treating the nerve damage that afflicts people with diabetes. The supplement is referred to as the “mother of all antioxidants” because it tends to support the activities of vitamins C and E, and other antioxidants. Since free radicals are thought to be a major part of the mechanism behind the nerve damage, it makes sense that ALA might have some protective effect. The nerve-protecting benefits of ALA for diabetics seem so convincing that some oncologists have begun recommending the supplement to cancer patients. In a 2003 issue of the Annals of Oncology, researchers at the University of Vienna (Austria) presented the first-ever study of cancer patients receiving ALA to counteract the neurotoxic effects of chemotherapy drugs. Fourteen people were enrolled in the study, including six with lung cancer, five with advanced gastric cancers, and three with head and neck tumors. The nerve-damaging drugs included Taxol and cisplatin. Each of these patients had reported experiencing numbness or tingling in either their hands or feet or both, and also had reported a burning sensation after receiving the chemotherapy. All 14 patients received 600 milligrams of ALA intravenously once a week for three to five weeks. This was followed by 1800 milligrams orally (600 mg three times a day) until they recovered fully from the neuropathy. Each patient took ALA for a maximum of six months. The study’s findings seemed to support the use of this antioxidant supplement. Eight out of the fourteen patients (57%) showed a favorable response to ALA. In six patients with moderate or grade 2 nerve damage, treatment with ALA resulted in a major improvement in neurological symptoms. In two patients who suffered from severe or grade 3 nerve damage, ALA supplementation brought substantial relief of symptoms. Some patients responded rapidly to ALA (within three weeks), while others took two to three months to respond. These findings indicate that ALA, when used to counteract chemotherapy-related neuropathy, may be able to stop and reverse the nerve-damaging effects of the anticancer drugs. No major side effects were reported from taking the ALA. In other research, ALA has shown some direct anticancer activities as well. Given the wide margin of safety for this supplement, ALA may indeed be considered a promising way to protect the nervous system during chemotherapy.
Sources
Gedlicka C, Kornek GV, Schmid K, Scheithauer W. Amelioration of docetaxel/cisplatin induced polyneuropathy by alpha-lipoic acid. Ann Oncol. 2003; 14(2):339-40.
Ziegler D, Hanefeld MH, Ruhnau KJ et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant -lipoic acid. A 7-month multicenter randomized controlled trial (ALADIN III Study).
Diabetes Care 1999; 22: 1296-1301
Rock E, Demark A. Nutritional approaches to late toxicities of adjuvant chemotherapy in breast cancer survivors. J. Nutr., November 1, 2003; 133(11): 3785S - 3793
